Guidelines for the Treatment of Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Traditional symptom-based therapies of irritable bowel syndrome (IBS) are directed at the relief of individual IBS symptoms, but they are often of limited efficacy in addressing the entire symptom complex. Combinations of drugs to target bothersome symptoms are suggested as the first-line pharmacologic treatment. Increasing knowledge of the pathophysiology and molecular mechanisms of IBS has resulted in the development of several new therapeutic approaches. Thirteen consensus statements for the treatment of IBS were developed using the modified Delphi approach. Exclusion diets have modest efficacy in improving symptoms in some IBS patients. Symptom-based therapies with dietary fiber, bulking agents, laxatives, antispasmodics and laxatives are effective in the improvement of some individual symptoms, e.g. dietary fiber and bulking agents for constipation, laxatives for constipation, antispasmodics for abdominal pain and discomfort, antidiarrheals for diarrhea. 5HT3 receptor antagonists and 5HT((4)) receptor agonists are effective in the relief of global IBS symptoms and individual symptoms such as abdominal pain and abnormal bowel habits. A short term course of nonabsorbable antibiotics may improve global IBS symptoms, particularly in patients with diarrhea- predominant IBS. Some probiotics appear to have the potential benefit in improving global IBS symptoms. Selective C-2 chloride channel activator is more effective than placebo at relieving global IBS symptoms in patients with constipation-predominant IBS. Both tricyclic antidepressants and selective serotonin reuptake inhibitors are equally effective in relieving global IBS symptoms, and have some benefits in treating abdominal pain. Certain types of psychologic therapy may be effective in improving global symptoms in some IBS patients. Further studies are strongly needed to develop better treatment strategies for Korean patients with IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gershon, M. D., & Tack, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.002 · Cited by 1,563
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448 · cited 1×
“나 복부팽만감 등 과민성 장 증상의 호전에 유의한 효과가 있었다.(90,91,93,95,97-100,104,105,108) 다른 균종에 대한 연구들로 40명의 과민성 장증후군 환자 들을 대상으로 4주간 Bacillus subtilis 및 Streptococcus faecium 균을 투여하였을 때 위약에 비해 복통의 빈도와 정”
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614 · cited 1×
“조연구에서 정신과적 치료는 과민성 장증후군의 증상을 효과 적으로 경감시켰다.(114,127-140) 이를 종합 분석한 결과에 따르면,”
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Ford, A. C., Talley, N. J., Spiegel, B. M. R., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M. M., & Moayyedi, P. (2008) · BMJ · doi:10.1136/bmj.a2313 · Cited by 565
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial
Atkinson, W., Sheldon, T. A., Shaath, N., & Whorwell, P. J. (2004) · Gut · doi:10.1136/gut.2003.037697 · Cited by 534
Food-Related gastrointestinal symptoms in the irritable bowel syndrome
Simrén, M., Månsson, A., Langkilde, A. M., Svedlund, J., Abrahamsson, H., Bengtsson, U., & Björnsson, E. S. (2001) · Digestion · doi:10.1159/000051878 · Cited by 529
Costabile, A., Klinder, A., Fava, F., Napolitano, A., Fogliano, V., Leonard, C., Gibson, G. R., & Tuohy, K. M. (2008) · British Journal of Nutrition · doi:10.1017/s0007114507793923 · Cited by 444 · cited 1×
“하지만 그 효과 는 그다지 크지 않으며, 아직까지 특정 음식을 제한하는 것이 어떤 기전을 통하여 효과를 나타내는지 명확하지 않다.(26,27)”
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., & Tomenson, B. (2003) · Gastroenterology · doi:10.1053/gast.2003.50055 · Cited by 443
Kim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., Thomforde, G., & Zinsmeister, A. R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00695.x · Cited by 400
Cited by
Ghoshal, U. C., Shukla, R., & Ghoshal, U. (2017) · Gut and Liver · doi:10.5009/gnl16126 · Cited by 204
“There are several approaches to treat SIBO among patients with IBS that include antibiotics, probiotics and prokinetics.(106) Dietary manipulation has potential influence on the gut microbiota that may relieve some of the symptoms of SIBO.”
BackgroundMüller, A., Franke, H., Resch, K.-L., & Fryer, G. (2014) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2014.098 · Cited by 88
Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition
Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., Shin, H. D., Lim, H. C., Shin, J. E., Kim, S. E., Cho, D. H., et al. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17145 · Cited by 47
“• Grade of recommendation: 1 • Level of evidence: B • Not voted in the revised edition Antispasmodics, including smooth muscle relaxants, antimuscarinic agents, anticholinergics, and calcium channel blockers, have long been used to treat IBS.”
BackgroundMethodInfluentialSchmulson, M., Bielsa, M. V., Carmona-Sánchez, R., Hernández, A., López-Colombo, A., López Vidal, Y., Peláez-Luna, M., Remes-Troche, J. M., Tamayo, J. L., & Valdovinos, M. A. (2014) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2014.01.004 · Cited by 29
(2009) · doi:10.4166/kjg.2019.73.2.84 · Cited by 11
Metadata
- Authors
- Kwon, J. G., Park, K. S., Park, J. H., Park, J. M., Park, C. H., Lee, K. J., Park, H.-J., Rhee, J. C., & The Korean Society of Neurogastroenterology and Motility
- Venue
- The Korean Journal of Gastroenterology
- Published
- 2011
- Volume
- 57
- Issue
- 2
- Pages
- 82
- ISSN
- 1598-9992 (ISSN-L)
- OpenAlex
- W2098351363
- Cited by
- 26
- References
- 40
- FWCI
- 2.04
- Type
- journal article
- Language
- ko
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.